Outcome of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia : Comparative retrospective two-institutional analysis /
Samah Ali Abdou Desoukey
Outcome of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia : Comparative retrospective two-institutional analysis / نتائج زرع النخاع العظمي الغير ذاتي في مرضي اللوكيميا الميلودية الحادة : دراسة تحليلية مقارنة ذو أثر رجعي بين معهدين Samah Ali Abdou Desoukey ; Supervised Hossam Kamel Mahmoud , Omar Abdelrahman Fahmy , Ahmed Galal - Cairo : Samah Ali Abdou Desoukey , 2014 - 318 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
Objectives: This study was intended to determine whether or not the outcome of allogeneic HSCT in patients diagnosed with AML at Nasser Institute was comparable to the outcome at the Princess Margaret Hospital. We also evaluated whether the EBMT risk score was able to predict the outcome after transplantation among the 2 cohorts. Results: The overall survival (OS) and transplant-related mortality (TRM) at 2 years were 68% and 27% among children and adolescents transplanted at Nasser Institute. The overall survival, Leukemia-free survival and TRM were 28%, 28% and of 65% for adults at Nasser Institute patients, respectively, and 50%, 50% and 36% for adults at PMH patients, respectively, at 2 years (p <0.0001). The relapse rate was 18% and 16% among Nasser Institute and PMH patients, respectively. The incidence of grade II-IV acute GVHD was 21% and 66% for Nasser Institute and PMH patients , respectively (p <0.0001), and that of chronic GVHD 36% and 50% (p=0.024). The EBMT risk score was predictive of the outcome among the cohorts. Survival rates decreased from 71% to 0% and TRM increased from 23% to 100 % with increasing risk scores from 0 to 4/5, respectively among Nasser Institute patients. Among PMH patients survival decreased from 70% to 16% and TRM increased from 14% to 60% with increasing risk scores from 1 to 5/6, respectively
Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation The EBMT risk score
Outcome of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia : Comparative retrospective two-institutional analysis / نتائج زرع النخاع العظمي الغير ذاتي في مرضي اللوكيميا الميلودية الحادة : دراسة تحليلية مقارنة ذو أثر رجعي بين معهدين Samah Ali Abdou Desoukey ; Supervised Hossam Kamel Mahmoud , Omar Abdelrahman Fahmy , Ahmed Galal - Cairo : Samah Ali Abdou Desoukey , 2014 - 318 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
Objectives: This study was intended to determine whether or not the outcome of allogeneic HSCT in patients diagnosed with AML at Nasser Institute was comparable to the outcome at the Princess Margaret Hospital. We also evaluated whether the EBMT risk score was able to predict the outcome after transplantation among the 2 cohorts. Results: The overall survival (OS) and transplant-related mortality (TRM) at 2 years were 68% and 27% among children and adolescents transplanted at Nasser Institute. The overall survival, Leukemia-free survival and TRM were 28%, 28% and of 65% for adults at Nasser Institute patients, respectively, and 50%, 50% and 36% for adults at PMH patients, respectively, at 2 years (p <0.0001). The relapse rate was 18% and 16% among Nasser Institute and PMH patients, respectively. The incidence of grade II-IV acute GVHD was 21% and 66% for Nasser Institute and PMH patients , respectively (p <0.0001), and that of chronic GVHD 36% and 50% (p=0.024). The EBMT risk score was predictive of the outcome among the cohorts. Survival rates decreased from 71% to 0% and TRM increased from 23% to 100 % with increasing risk scores from 0 to 4/5, respectively among Nasser Institute patients. Among PMH patients survival decreased from 70% to 16% and TRM increased from 14% to 60% with increasing risk scores from 1 to 5/6, respectively
Acute myeloid leukemia Allogeneic hematopoietic stem cell transplantation The EBMT risk score